Jeremy D Jokinen (Jeremy Jokinen)

ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 8

Top Venues

Therapeutic innovation & regulatory science

Drug safety

Expert opinion on drug safety

Pharmacoepidemiology and drug safety

Bristol-Myers Squibb

Ohio University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Bristol-Myers Squibb Jun 01 2020

United States

Head Business Capabilities and Innovation :: Worldwide Patient Safety

AbbVie Inc Nov 15 2015 - May 31 2020

United States

Sr Director :: Pharmacovigilance and Patient Safety

Education History

Ohio University - Dec 01 2015

United States

PHD :: Psychology

Publications

Joanne Treacy, Elaine H Morrato, Robert Horne, Michael S Wolf, Ameet Bakhai, Marie-Claire Wilson, Mark Lightowler, Sibel Guerler, Jeremy D Jokinen
Behavioral Science: Enhancing Our Approach to the Development of Effective Additional Risk Minimization Strategies. Drug safety 47 (8) (2024)
Joanne Treacy, Elaine H Morrato, Robert Horne, Michael S Wolf, Ameet Bakhai, Marie-Claire Wilson, Mark Lightowler, Sibel Guerler, Jeremy D Jokinen
Behavioral Science: Enhancing Our Approach to the Development of Effective Additional Risk Minimization Strategies. Drug safety (2024)
Jeremy D Jokinen, Rosalind J Walley, Michael W Colopy, Thomas S Hilzinger, Peter Verdru
Pooling Different Safety Data Sources: Impact of Combining Solicited and Spontaneous Reports on Signal Detection In Pharmacovigilance. Drug safety 42 (10) (2020)
Inyoung Lee, Jeremy D Jokinen, Stephanie Y Crawford, Gregory Sampang Calip, Ryan D Kilpatrick, Todd A Lee
Exploring Completeness of Adverse Event Reports as a Tool for Signal Detection in Pharmacovigilance. Therapeutic innovation & regulatory science 55 (1) (2020)
Inyoung Lee, Todd A Lee, Stephanie Y Crawford, Ryan D Kilpatrick, Gregory Sampang Calip, Jeremy D Jokinen
Impact of adverse event reports from marketing authorization holder-sponsored patient support programs on the performance of signal detection in pharmacovigilance. Expert opinion on drug safety 19 (10) (2020)
Jeremy D Jokinen, Dominique Bertin, Bruce Donzanti, Janet Hormbrey, Valerie Simmons, Hal Li, Charles Dharmani, Karolyn Kracht, Thomas S Hilzinger, Peter Verdru
Industry Assessment of the Contribution of Patient Support Programs, Market Research Programs, and Social Media to Patient Safety. Therapeutic innovation & regulatory science 53 (6) (2019)
Jeremy D Jokinen, Fabio Lievano, Linda Scarazzini, Melissa Truffa
An Alternative to Disproportionality: A Frequency-Based Method for Pharmacovigilance Data Mining. Therapeutic innovation & regulatory science 52 (3) (2017)
Fabio Lievano, Linda Scarazzini, Frank Shen, James Duhig, Jeremy D Jokinen
The future of safety science is happening now: The modernization of the benefit-risk paradigm. Pharmacoepidemiology and drug safety 26 (8) (2017)

Jeremy D Jokinen.css-eqlu8i{font-size:small;padding-left:4px;} (Jeremy Jokinen)

Publication Activity (10 Years)

Top Topics

Top Venues

Jeremy D Jokinen (Jeremy Jokinen)